TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05307055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STN DBS - Theta Burst
Description: 200 Hz intraburst stimulation for 0.1 second repeated at intervals of 5hz with an existing device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STN DBS - Theta Burst
Description: 200 Hz intraburst stimulation for 0.1 second repeated at intervals of 5hz with an existing device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STN DBS - Gamma
Description: Standard of care gamma stimulation with an existing device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STN DBS - Gamma
Description: Standard of care gamma stimulation with an existing device
Study: NCT05493280

Intervention type: DEVICE
Group type: OTHER
Intervention: MOXI
Description: Patients will receive treatment using f1927 devices and will be treated over the affected areas, once each month for a total of three months.

Intervention type: DEVICE
Group type: OTHER
Intervention: MOXI
Description: Patients will receive treatment using f1927 devices and will be treated over the affected areas, once each month for a total of three months.
Study: NCT06386510

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Strength training
Description: The strength training program will last 4 weeks (3 X/week, 60 minutes). Using dead weights, the 1RM (i.e. the maximal load that an individual can lift once) will be estimated by the 10RM for the wrist extensors and the elbow and shoulder flexors. The grip muscles of the affected hand will also be trained with a JAMAR® dynamometer. Depending on each participant's intensity training group, training will start at 35%, 50% or 70% of 1RM and will be increased by 5% each week to reach, by week 4, 50%, 65% and 85%, for the low, moderate, and high-intensity group, respectively.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cranial nerve non-invasive neuromodulation
Description: For the first 20 minutes of each training session, CN-NINM will be applied (50 μsec at 150 Hz), using a portable stimulator (Cthulhu Shield, USA) with a network of 18 electrodes, directly on the participants' tongue. The participants will hold the device in place by pressing their tongue upwards and the intensity of the stimulus will be set by each participant to a comfortable level of sensation (experimental group) or set by a trainer to a non-perceivable stimulus (control group).
Study: NCT06042894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: BL-B01D1 was administered by intravenous infusion on D1 and D8 in a 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B003
Description: SI-B003 was administered by intravenous infusion on D1 in a 3-week cycle.
Study: NCT04636801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: CHF6001 1600µg
Description: CHF6001 400µg, 2 inhalations bid (total daily dose of 1600µg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: CHF6001 3200µg
Description: CHF6001 800µg, 2 inhalations bid (total daily dose of 3200µg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: CHF6001 matching placebo, 2 inhalations bid.
Study: NCT04550715

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief intervention (BI)
Description: A remote brief intervention delivered by health coaches that uses Motivational Interviewing to address opioid misuse and risk factors. Remote health coaches use a web-based clinician support guide to maintain fidelity, while tailoring the session to unique participant factors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief intervention (BI)
Description: A remote brief intervention delivered by health coaches that uses Motivational Interviewing to address opioid misuse and risk factors. Remote health coaches use a web-based clinician support guide to maintain fidelity, while tailoring the session to unique participant factors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Portal
Description: Remote health coaches will push tailored messages to participants over a 4-week period. The messages will use Motivational Interviewing strategies. The messages are designed to elicit a response from the participant. Health coaches will also respond to participant replies consistent with Motivational Interviewing over a course of 4 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Portal
Description: Remote health coaches will push tailored messages to participants over a 4-week period. The messages will use Motivational Interviewing strategies. The messages are designed to elicit a response from the participant. Health coaches will also respond to participant replies consistent with Motivational Interviewing over a course of 4 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care (EUC)
Description: The brochure covers educational topics like opioid storage and disposal and overdose prevention, as well as resources such as naloxone, suicide hotlines, mental health, and substance use treatment. It will be available online and in print.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: The brochure covers educational topics like opioid storage and disposal and overdose prevention, as well as resources such as naloxone, suicide hotlines, mental health, and substance use treatment. It will be available online and in print.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care (EUC)
Description: The brochure covers educational topics like opioid storage and disposal and overdose prevention, as well as resources such as naloxone, suicide hotlines, mental health, and substance use treatment. It will be available online and in print.
Study: NCT06133088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalpiciclib; fluvestrant; compound gossypol acetate tablets
Description: Darcilie: 150mg orally for three weeks and stop for one week. Fluvestrant: 500mg every four weeks. A further 500mg dose two weeks after the first dose.~Compound gossyrol acetate tablet: 20mg daily.
Study: NCT06398145

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D-chiro-inositol and lactalbumin (high dose)
Description: From 0 to 3 months: 1200mg D-chiro-inositol and 120mg lactalbumin per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D-chiro-inositol and lactalbumin (low dose)
Description: From 3 to 6 months: 600mg D-chiro-inositol and 60mg lactalbumin per day
Study: NCT04262375

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is a human immunoglobulin G (IgG)1 kappa monoclonal antibody directed against human PD-L1. Durvalumab selectively binds human PD-L1 with high affinity and blocks its ability to bind to PD-1 and cluster of differentiation (CD)80. The fragment crystallizable (Fc) domain of durvalumab contains a triple mutation in the constant domain of the IgG1 heavy chain that reduces binding to the complement component C1q and the Fc gamma receptors responsible for mediating antibody dependent cell mediated cytotoxicity.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Oleclumab is a human immunoglobulin G1 lambda monoclonal antibody (mAb) with a triple mutation in the heavy chain constant region for reduced effector function. Oleclumab selectively binds to cluster of differentiation 73 (ecto-5'-nucleotidase) (CD73) and inhibits CD73-associated ectonucleotidase activity, thereby inhibiting the CD73-mediated production of immunosuppressive adenosine. Extracellular adenosine contributes to the immunosuppressive effects of both regulatory T cells and myeloid derived suppressor cells, among others. This, in turn, leads to increased antitumor immunity.
Study: NCT06386510

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cranial nerve non-invasive neuromodulation
Description: For the first 20 minutes of each training session, CN-NINM will be applied (50 μsec at 150 Hz), using a portable stimulator (Cthulhu Shield, USA) with a network of 18 electrodes, directly on the participants' tongue. The participants will hold the device in place by pressing their tongue upwards and the intensity of the stimulus will be set by each participant to a comfortable level of sensation (experimental group) or set by a trainer to a non-perceivable stimulus (control group).
Study: NCT06459921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOX+Sintilimab
Description: Patients would be allocated to the SOX+Sintilimab group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLOT+Sintilimab
Description: Patients would be allocated to the FLOT+Sintilimab group.
Study: NCT05403762

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESENTA™ Skin Barrier Spray (ConvaTec, UK)
Description: The skin protectant will be applied on clean and dry skin exposed to urine and stool. After application, the solvent evaporates leaving a silicone film on the skin surface.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrophobes Basisgel DAC
Description: The skin protectant will be applied on clean and dry skin. It contains 95% paraffin oil and creates a hydrophobic layer on the skin surface.
Study: NCT06636240

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mulberry fruit juice
Description: Mulberry fruit juice 200ml/day plus standard therapy for atopic dermatitis including Fluticasone and Prednisolone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone
Description: Standard therapy for atopic dermatitis including Fluticasone and Prednisolone
Study: NCT05805397

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivation Skills Training
Description: Participants will complete a baseline assessment, receive weekly MST sessions in a group format for a duration of 12 weeks, and will then repeat the assessment battery from baseline immediately following treatment completion and 2-months after.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Behaviors Control Group
Description: Participants will complete a baseline assessment, receive weekly HBC sessions in a group format for a duration of 12 weeks, and will repeat the assessment battery from baseline immediately following treatment completion and 2-months after.
Study: NCT06060171

Intervention type: PROCEDURE
Intervention: Aortic valve intervention
Description: Surgical or transcatheter aortic valve intervention

Intervention type: PROCEDURE
Intervention: Aortic valve intervention
Description: Surgical or transcatheter aortic valve intervention
Study: NCT06012760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron sucrose, Human Erythropoietin Injection, Vitamin C
Description: The participants were administered a combined iron supplementation regimen consisting of iron sucrose,Human Erythropoietin Injection, and vitamin C, three times throughout the preoperative week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Care
Description: Standard Medical Care (SMC) for the treatment of IDA. SMC as determined by the Investigator for the treatment of iron deficiency anemia (IDA).
Study: NCT05909865

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic resistance exercise
Description: Therapeutic exercise program based on individualized progressive resistance exercises performed during 3 months at home, with a frequency of 1-3 sessions per week at the hospital.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Education applied during all the therapeutic process, focusing on diverting the patient's attention away from the structural lesion, explaining the relationship between pain/disability and tissue injury, explaining the meaning of pain during exercises, and explaining the objectives of the implemented treatments.
Study: NCT04586049

Intervention type: DEVICE
Intervention: MRI
Description: Participants will undergo an MRI scan while participating in a breathing test to measure brain blood flow.
Study: NCT04586049

Intervention type: DEVICE
Intervention: MRI
Description: Participants will undergo an MRI scan while participating in a breathing test to measure brain blood flow.

Intervention type: DEVICE
Intervention: Transcranial Doppler Ultrasound
Description: Participants will undergo a TCD scan while participating in a breathing test to measure brain blood flow.
Study: NCT04882683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 0.75 mg per kilogram per day for three months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 0.75 mg per kilogram per day for three months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: 1 mg per kilogram per day for three months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: 1 mg per kilogram per day for three months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: 40mg every two weeks for three months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: 40mg every two weeks for three months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord blood mononuclear cells
Description: Peripheral intravenous infusion method, infusion of umbilical cord blood mononuclear cell suspension 50ml (cell number 2×10\^8).
Study: NCT05751395

Intervention type: DEVICE
Intervention: Central Venous Access
Description: Critically ill patients in severe MODS need a CVC and in some cases also a second line for e-g- blood purification techniques.~All CVCs are positioned via the ECG method with the CVC tip placed at P-max. Within 24 h a chest radiograph is obtained for assessment of the CVCs, especially their tips.
Study: NCT06383377

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth extraction and bone graft procedure
Description: The subject will receive a flash dose of 2 gr of amoxicillin or 600 mg of Clindamycin 1 hour before the surgery.~Tooth will be extracted using gentle techniques to guarantee an atraumatic extraction. If the socket presents insufficient bleeding, the clinician must use an appropriate procedure to induce bleeding. The extraction site must be carefully cleaned. Extraction socket will then be filled with WHA or Bio-Oss previously hydrated with saline solution (0.9%). Extraction socket packed with the graft will be covered with a collagen sponge (Geistlich Mucograft® Seal) and sutured (cross suture, Vicryl rapide 4.0).~If required, a limited connective tissue graft can be placed in the vestibular region.~A CBCT scan will be performed after the bone graft procedure, i.e., after the extraction socket and the biomaterial placement, to measure the initial bone width.~The safety of the investigational device will be evaluated.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tooth extraction and bone graft procedure
Description: The subject will receive a flash dose of 2 gr of amoxicillin or 600 mg of Clindamycin 1 hour before the surgery.~Tooth will be extracted using gentle techniques to guarantee an atraumatic extraction. If the socket presents insufficient bleeding, the clinician must use an appropriate procedure to induce bleeding. The extraction site must be carefully cleaned. Extraction socket will then be filled with WHA or Bio-Oss previously hydrated with saline solution (0.9%). Extraction socket packed with the graft will be covered with a collagen sponge (Geistlich Mucograft® Seal) and sutured (cross suture, Vicryl rapide 4.0).~If required, a limited connective tissue graft can be placed in the vestibular region.~A CBCT scan will be performed after the bone graft procedure, i.e., after the extraction socket and the biomaterial placement, to measure the initial bone width.~The safety of the investigational device will be evaluated.
Study: NCT04586049

Intervention type: DEVICE
Intervention: Transcranial Doppler Ultrasound
Description: Participants will undergo a TCD scan while participating in a breathing test to measure brain blood flow.

Intervention type: OTHER
Intervention: Sympathetic Nerve Activity
Description: Participants will undergo sympathetic nerve activity testing while participating in a breathing test.

Intervention type: OTHER
Intervention: Sympathetic Nerve Activity
Description: Participants will undergo sympathetic nerve activity testing while participating in a breathing test.
Study: NCT06009900

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low intensity laser treatment
Description: Low intensity laser treatment: Both patients and doctors wear goggles during the irradiation process. Using 810nm (infrared)/658nm (red) dual wavelength output for direct skin contact point irradiation, the maximum output power is 100mW (red)/60mW (infrared). Select the treatment site based on the patient's anatomical positioning (muscle and tendon attachment points, nerve distribution aggregation points) and/or pain points, and perform spot laser irradiation. Low intensity laser treatment process: Treat once a day for 15 minutes each time, with 5 consecutive days of treatment and 2 days of rest per week. The patient received a total of 3 weeks (15 times) of low intensity laser treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-steroidal drug (Celecoxib) group
Description: Oral Celecoxib 200mg/time, twice a day, for three consecutive weeks.
Study: NCT04184375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive stimulation
Description: Patients participate in one session per week according to the following schedule:~* 2 sensory stimulation sessions: identify sensations, emotions, how to manage them.~* 2 sessions on association, verbal fluency, and imagination: language as a tool for expression in the face of illness.~* 2 voluntary attention sessions: improve daily attention.~* 2 sessions of intellectual structuring: stimulating and maintaining memory, carrying out external activities.~* 2 sessions of structuring through language: impact on social life.~* 2 sessions stimulating the temporal and spatial landmarks: agenda, daily trips.
Study: NCT05872074

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Coronary angiography plus percutenous coronary intervention
Description: 1. wire both branches, MV and SB, with two coronary guide wires.~2. Main branch pre-dilation~3. Side branch pre-dilation using (ordinary balloon in group A and Drug coated balloon in group B for the side branch)~4. Main vessel stenting~5. Proximal optimization technique (POT) of the main vessel stent
Study: NCT05610930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Front-of-pack label NutriScore 2.0
Description: Participants in the experimental arm can see, in case the product is ultra-processed, a black banner surrounding the Nutri-Score, with the word ultra-transformé, meaning ultra-processed, and no black banner otherwise. Participants in the control arm had no label at all. The intervention (the Nutri-Score 2.0) was added on the packaging on the products included in the 3 sets of images that participants recieved via the questionnaire.
Study: NCT06471842

Intervention type: OTHER
Intervention: MCH (Montreal Children's Hospital) feeding scale questionnaire and parental questionnaire
Description: The patient's parents will answer the questionnaire and the investigator will complete the parental questionnaire while asking the questions.
Study: NCT06312085

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endofill
Description: Endofill is intended for the permanent obturation of root canals following root canal preparation and disinfection.
Study: NCT05747365

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood and urine diagnostic evaluation
Description: Blood and urine samples will be obtained from both case and control groups in order to evaluate EDCs concentrations

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood and urine diagnostic evaluation
Description: Blood and urine samples will be obtained from both case and control groups in order to evaluate EDCs concentrations
Study: NCT06093828

Intervention type: DEVICE
Group type: OTHER
Intervention: TriFlo Tricuspid Flow Optimizer
Description: An introducer sheath is inserted into the femoral vein over a stiff guidewire; the sheath extends into the common iliac vein and inferior vena cava and in the right atrium. The TFO device is oriented coaxiality to the tricuspid. Once released, the delivery catheter and the steerable catheter are removed the access site closure performed by a cardiovascular or vascular surgeon or with pre-implanted percutaneous sutures per site preference.
Study: NCT06458725

Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: - Three MRI :~* two on an MR-Linac 1.5 Tesla (10 to 17 days apart)~* one on a standard 1.5 Tesla MRI
Study: NCT05940883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y-2 Sublingual Tablet
Description: Subjects will receive one Y-2 sublingual tablet sublingually once daily for Day1 and Day 19 and twice daily for Day 6 to Day 18.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y-2 Sublingual Tablet
Description: Subjects will receive two Y-2 sublingual tablets sublingually once daily for Day1 and Day 19 and twice daily for Day 6 to Day 18.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y-2 Sublingual Tablet
Description: Subjects will receive Y-2 sublingual tablet with 3 different conditions once daily for Day1 Day 6 and Day 11. Day 1 with condition A, Day 6 with condition B and Day 11 with condition C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y-2 Sublingual Tablet
Description: Subjects will receive Y-2 sublingual tablet with 3 different conditions once daily for Day1 Day 6 and Day 11. Day 1 with condition B, Day 6 with condition C and Day 11 with condition A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y-2 Sublingual Tablet
Description: Subjects will receive Y-2 sublingual tablet with 3 different conditions once daily for Day1 Day 6 and Day 11. Day 1 with condition C, Day 6 with condition A and Day 11 with condition B.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, sublingually, single and multiple ascending dosing in group 1 and 2 subjects.
Study: NCT05521490

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care Control
Description: 30 minutes of physical activity on each school day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Enhanced Curriculum
Description: Additional 2.5 hours of physical activity per week in addition to the stipulated 30 minutes of daily physical activity.
Study: NCT05771311

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KTP
Description: split-side, 1 -5 sessions at intervals of 6 - 8 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PDL
Description: split-side, 1 -5 sessions at intervals of 6 - 8 weeks